查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1914506

心臟靶向胜肽市場（按產品類型、遞送系統、分子類型、應用和最終用戶分類）—全球預測，2026-2032年

Cardiac Targeting Peptides Market by Product Type, Delivery System, Molecule Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年心臟標靶胜肽市場價值為 2.488 億美元，預計到 2026 年將成長至 2.6304 億美元，複合年成長率為 4.57%，到 2032 年將達到 3.4027 億美元。

關鍵市場統計數據
基準年 2025 2.488億美元
預計年份：2026年 2.6304億美元
預測年份 2032 3.4027億美元
複合年成長率 (%) 4.57%

全面介紹心臟標靶胜肽：科學基礎、臨床需求與轉化挑戰如何影響專案開發

心臟標靶胜肽旨在透過整合胜肽化學、分子影像學和標靶治療，解決心血管疾病診斷和治療中長期存在的挑戰。這些分子被設計成能夠選擇性地結合心臟組織或疾病特異性生物標記物，從而實現精準成像、標靶藥物遞送或診斷和治療的雙重功能。人口結構的變化和慢性疾病負擔的日益加重，促使臨床醫生對那些與傳統小分子化合物和全身性生技藥品相比，具有更高特異性和更低脫靶效應的治療方式產生了濃厚的興趣。

新興的產業趨勢揭示了多功能胜肽結構、先進的遞送系統和運算設計如何重塑轉化研究路徑。

在技​​術創新和不斷變化的臨床需求的驅動下，心血管胜肽領域正經歷著變革性的轉變。其中最顯著的是多功能構建體的興起，模糊了診斷和治療之間的界線。能夠同時遞送影像造影造影和治療藥物的製劑正從概念驗證研究階段邁向早期轉化評估階段。這種整合使得標靶結合和動態的即時評估成為可能，從而縮短了研發週期並促進了適應性研究設計的發展。

分析2025年關稅變化如何影響胜肽和輔料的採購、生產決策、臨床試驗時間表以及策略供應鏈的韌性

2025年實施的新關稅給支持胜肽合成和藥物製劑的全球供應鏈帶來了巨大壓力。關鍵原料，例如特殊胺基酸、保護試劑和偶聯連接劑，都受到國際貿易的影響，而關稅的提高增加了到岸成本，並使研發人員和契約製造的籌資策略變得更加複雜。因此，依賴單一供應商或跨境組件組裝的企業即時感受到成本和進度的影響，迫使它們迅速重新談判供應合約並重新評估替代原料。

策略性細分洞察：揭示產品類型、臨床用途、最終用戶、給藥平台和分子結構對研發路徑的影響

了解細分市場對於專案優先順序至關重要，因為產品類型、應用、最終用戶、遞送系統和分子結構各自存在不同的權衡取捨，這些都會影響開發策略和價值創造。按產品類型分類，診斷胜肽針對生物標記檢測和成像進行了最佳化。生物標記檢測劑進一步分為生物感測器探針和免疫檢測相容的ELISA探針，而成像劑通常設計為MRI造影肽或PET示蹤劑，每種都需要不同的放射性核素化學性質和穩定性要求。雙功能胜肽結合了成像和治療功能，包括旨在將藥物遞送與整合成像功能相結合的結構，以及旨在同時進行成像引導治療的結構。後者可以顯著縮短標靶結合與臨床療效之間的證據差距。治療胜肽則著重於血管生成、抗凋亡訊號傳導和心臟保護等生物學結果。血管新生候選藥物通常來自纖維母細胞生長因子或血管內皮生長因子模擬物，抗凋亡方法涉及 Bcl-2調變器或 caspase 抑制劑，而心臟保護策略則針對缺血再灌流傷害和心肌梗塞修復。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢將影響臨床試驗准入、監管互動和商業化路徑。

區域背景至關重要，因為全球各市場的研究強度、管理體制、商業基礎設施和報銷途徑各不相同，這將對研發和上市策略產生重大影響。在美洲，學術醫療中心和專科心臟病診所的集中分佈，以及成熟的創投製藥生態系統，加速了轉化研究的進程，並促進了臨床試驗網路的建立。該地區的監管機構已為影像劑和治療性胜肽類藥物建立了核准途徑，支付方也越來越接受那些能夠展現明確診斷價值或減少後續干預措施的技術。這有可能縮短那些能夠產生可靠臨床證據的項目的商業性化。

企業能力、夥伴關係模式和智慧財產權策略塑造了胜肽類藥物研發領域的競爭優勢和轉化成功。

在心臟標靶胜肽領域，企業策略的差異體現在核心能力、產品組合重點和資本密集度等。大型製藥企業傾向於將胜肽類藥物專案整合到其更廣泛的心血管業務中，利用內部監管專業知識、成熟的生產網路和全球商業化管道來降低後期研發的風險。中型生物技術公司和專業Start-Ups則通常專注於透過分子設計和製劑創新，開發具有競爭優勢的差異化平台技術和針對特定適應症的藥物。這些規模小規模的公司通常會優先考慮早期在人體中驗證藥物的作用機制，然後尋求合作夥伴關係和許可協議，以確保關鍵性試驗和商業化所需的資源。

透過專案優先排序、供應鏈強化以及監管和商業策略的協調，為經營團隊切實可行的建議，幫助他們快速取得成效。

產業領導者應採取雙軌策略，兼顧近期診斷和遞送技術機會與長期治療目標。務實地講，優先發展監管路徑清晰的計劃，例如成像劑和標靶遞送系統，將創造早期檢驗機會和收入來源，從而支持高風險治療項目。同時，投資可靠的臨床前模型和轉化生物標記物，將提高心臟保護和血管生成候選藥物展現臨床意義訊號的可能性。

本文描述了一種混合方法研究框架，該框架整合了初步訪談、文獻綜述、專利映射、監管分析和檢驗，以確保研究結果的可靠性。

本分析所依據的研究結合了定性和定量方法，以確保擁有強力的、多維度的證據基礎。主要研究包括對轉化和臨床研究人員、生產專家以及商業領袖進行結構化訪談，以收集有關技術挑戰和策略決策點的第一手資料。次要研究包括對同儕審查文獻、臨床試驗註冊庫、專利概況和監管指導文件進行系統性回顧，以檢驗論點並識別影響研發選擇的領先。

簡明扼要地總結了科學進展、營運需求和戰略重點，這些因素將決定心臟標靶胜肽計畫的成功。

總之，心臟標靶胜肽代表著一個多方面的機會領域，它將精準診斷、標靶遞送和新型治療方法連結起來。分子設計、偶聯化學和遞送平台的技術進步正在匯聚，以克服過去在穩定性、生物分佈和靶向特異性方面的局限性。同時，商業性和監管方面的複雜性要求制定周密的策略，以降低研發風險，並向臨床醫生和支付方證明其價值。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 按產品類型分類的心臟標靶胜肽市場

  • 診斷胜肽
    • 生物標記檢測劑
      • 生物感測器探針
      • ELISA探針
    • 影像劑
      • MRI造影肽
      • 寵物追蹤器
  • 雙功能胜肽
    • 藥物遞送成像胜肽
    • 影像治療胜肽
  • 治療性胜肽
    • 血管生成胜肽
      • FGF模擬胜肽
      • VEGF模擬胜肽
    • 抗凋亡胜肽
      • Bcl2調節胜肽
      • 半胱天冬酶抑制胜肽
    • 心臟保護胜肽
      • 缺血再灌流傷害肽
      • 心肌梗塞胜肽

9. 按遞送系統分類的心臟標靶胜肽市場

  • 脂質體綴合物
    • 傳統脂質體
      • 陽離子脂質體
      • 中性脂質體
    • 隱形脂質體
      • 甘露糖修飾的脂質體
      • 聚乙二醇化脂質體
  • 奈米顆粒綴合物
    • 金奈米粒子
      • 棒狀金奈米粒子
      • 球形金奈米粒子
    • 脂質奈米顆粒
      • 奈米乳液
      • 固體脂質奈米顆粒
    • 聚合物奈米粒子
      • 幾丁聚醣顆粒
      • PLGA奈米顆粒
  • 聚合物共軛物
    • PEG綴合物
      • 支鏈聚乙二醇綴合物
      • 鎖狀PE​​G綴合物
    • PLGA綴合物
      • 細顆粒物
      • 奈米顆粒

第10章：以分子類型分類的心臟標靶胜肽市場

  • 環肽
    • 二硫鍵環化
      • 單二硫化物
      • 多二硫化物
    • 顱尾方向環化
      • 核心回收
      • 側鏈環化
  • 基於樹狀聚合物肽
    • PAMAM樹狀聚合物
      • 第四代
      • 第五代
    • PPI樹狀聚合物
      • 第三代
      • 第四代
  • 線性胜肽
    • 長鏈胜肽
      • 21至50種氨基酸
      • 50種或更多氨基酸
    • 短胜肽
      • 10至20種氨基酸
      • 少於10個氨基酸

第11章：心臟標靶胜肽市場（按應用領域分類）

  • 診斷影像
    • 磁振造影
      • 钆標記胜肽
      • 氧化鐵結合胜肽
    • PET影像
      • 氟-18標記胜肽
      • 鎵-68標記胜肽
    • 超音波影像
  • 標靶藥物遞送
    • 基於水凝膠的遞送
      • 可注射水凝膠
      • 熱響應性水凝膠
    • 脂質體遞送
      • 聚乙二醇化脂質體
      • pH敏感脂質體
    • 奈米顆粒遞送
      • 金奈米粒子
      • 棒狀金奈米粒子
      • 球形金奈米粒子
      • 氧化鐵奈米顆粒
  • 治療
    • 心律不整控制
    • 心臟衰竭治療
      • Hfpef治療胜肽
      • HFref治療性胜肽
    • 心肌梗塞的治療
      • 急性心肌梗塞胜肽
      • 慢性心肌梗塞修復肽

第12章：按最終用戶分類的心臟靶向胜肽市場

  • 醫院和診所
    • 心臟診所
      • 門診部
      • 手術中心
    • 三級醫院
      • 私立醫院
      • 公立醫院
  • 製藥公司
    • 大型製藥公司
    • 生技公司
      • 中型生技公司
      • 小規模生技公司
  • 研究所
    • 學術機構
      • 政府研究機構
      • 大學
    • CRO
      • 臨床合約研究組織
      • 臨床前合約研究組織

13. 各地區心臟標靶胜肽市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：心臟標靶胜肽市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各國心臟標靶胜肽市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章美國心臟標靶胜肽市場

第17章：中國心臟標靶胜肽市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Acesion Pharma
  • Amgen Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Ferring Pharmaceuticals Inc.
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi SA
Product Code: MRR-AE420CB1529D

The Cardiac Targeting Peptides Market was valued at USD 248.80 million in 2025 and is projected to grow to USD 263.04 million in 2026, with a CAGR of 4.57%, reaching USD 340.27 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 248.80 million
Estimated Year [2026] USD 263.04 million
Forecast Year [2032] USD 340.27 million
CAGR (%) 4.57%

A comprehensive introduction to cardiac targeting peptides explaining scientific foundations, clinical imperatives, and translational challenges shaping program development

Cardiac targeting peptides represent a convergence of peptide chemistry, molecular imaging, and targeted therapeutics that seeks to address persistent gaps in the diagnosis and treatment of cardiovascular disease. These molecules are engineered to bind selectively to cardiac tissue or disease-specific biomarkers, enabling precision imaging, focused drug delivery, or combined diagnostic-therapeutic functionality. As demographic shifts and chronic disease burdens intensify, the clinical community is increasingly attracted to modalities that promise higher specificity and fewer off-target effects compared with traditional small molecules or systemic biologics.

Transitioning these constructs from concept to clinic requires alignment across discovery, formulation, manufacturing, and regulatory pathways. Innovations in peptide cyclization, dendrimer scaffolds, and nanoparticle conjugation have broadened the design space, while advances in imaging chemistry and delivery systems have improved in vivo stability and targeting performance. Stakeholders spanning academic researchers, biotech ventures, contract research organizations, and established pharmaceutical groups are all engaging to translate promising preclinical findings into human studies. As a result, strategic choices around molecule type, delivery system, and intended application increasingly determine the feasibility and speed of development.

In the near term, diagnostic imaging and targeted drug delivery applications are driving pragmatic, translational work, because they can leverage existing imaging infrastructure and clinical endpoints. Over the medium term, therapeutic peptides designed for cardioprotection, angiogenesis, and anti-apoptotic effects present compelling biological rationales but demand robust evidence of durable benefit and safety. Given these dynamics, a disciplined, evidence-led approach to target selection, conjugation strategy, and clinical trial design is essential to capture the available clinical and commercial opportunities effectively.

Emerging industry shifts reveal how multifunctional peptide constructs, advanced delivery systems, and computational design are reshaping translational pathways

The cardiovascular peptide landscape is undergoing transformative shifts driven by technical innovation and evolving clinical expectations. The most visible change is the rise of multifunctional constructs that blur the line between diagnostics and therapeutics; agents that simultaneously deliver imaging contrast and therapeutic payloads are moving from proof-of-concept studies to early translational evaluation. This integration enables real-time assessment of target engagement and pharmacodynamics, which in turn can compress development cycles and inform adaptive trial designs.

Concurrently, delivery science has matured sufficiently to permit more reliable targeting in vivo. Liposomal and nanoparticle conjugates, together with polymer-based carriers, have increased circulation time and reduced immunogenicity for peptide cargoes. Advances in PEGylation chemistries, dendrimer architectures, and stimulus-responsive hydrogel matrices have enabled more controlled release profiles and tissue residency, thereby widening clinical applicability. As an outcome, programs that once failed due to rapid clearance or off-target toxicity are being revisited with optimized formulations.

Another key shift is the increased use of computational design and high-throughput screening to accelerate lead identification. Machine learning approaches and structural modeling are being applied to predict binding motifs, stability profiles, and off-target interactions, enabling more rational candidate selection. At the ecosystem level, partnerships between academic groups, specialized biotech firms, and clinical centers are growing more strategic, focused on co-development models and shared manufacturing investments. Collectively, these shifts are creating a more cohesive innovation pathway that links early discovery directly to clinical proof of mechanism and, ultimately, to patient impact.

Analysis of how 2025 tariff changes have reshaped peptide and excipient procurement, manufacturing decisions, clinical timelines, and strategic supply chain resilience

The introduction of new tariff measures in 2025 created material pressure across global supply chains that underpin peptide synthesis and formulation. Key raw materials such as specialty amino acids, protective reagents, and conjugation linkers are subject to international trade flows; increased duties have raised landed costs and complicated procurement strategies for developers and contract manufacturers. As a result, organizations reliant on single-source suppliers or on cross-border component assembly experienced immediate cost and scheduling impacts, necessitating rapid renegotiation of supplier agreements and in some cases requalification of alternative inputs.

Beyond reagents, tariff effects propagated into the supply chain for delivery system components. Import costs for lipid excipients, gold or iron oxide nanoparticles, and specialized polymers have increased, prompting many developers to re-evaluate formulation choices and to accelerate qualification of domestically available substitutes. This re-evaluation has implications for product performance and regulatory submissions, because even minor changes in excipient profiles can require additional comparability studies or bridging data to satisfy regulators.

Clinical development and manufacturing timelines were also affected. Increased component costs have led some small and mid-size firms to delay initiation of pivotal studies or to seek co-development partnerships to share financial burdens. At the same time, larger firms have reassessed their outsourcing strategies, with several favoring increased vertical integration or nearshoring to mitigate tariff exposure. These strategic shifts have implications for capacity planning among contract development and manufacturing organizations, and they are reshaping investment priorities within corporate portfolios.

Finally, the tariffs accelerated conversations about resilience. Companies that invested earlier in supplier diversification, dual sourcing, and inventory buffering demonstrated greater operational continuity. Looking forward, regulatory and payer stakeholders are likely to view supply chain robustness as a component of product reliability, which underscores the need for transparent documentation and contingency planning during development and commercialization.

Strategic segmentation insights revealing how product types, clinical uses, end users, delivery platforms, and molecular architectures influence development pathways

Understanding segmentation is critical for program prioritization because product type, application, end user, delivery system, and molecule architecture each carry distinct tradeoffs that influence development strategy and value creation. Within product typologies, diagnostic peptides can be optimized either for biomarker detection or for imaging; biomarker detection agents split further into biosensor probes and immunoassay-compatible ELISA probes, while imaging agents are typically designed as MRI contrast peptides or PET tracers, each demanding different radionuclide chemistry and stability constraints. Dual function peptides merge imaging and therapeutic capabilities, encompassing constructs tailored to drug delivery with integrated imaging functionality and those designed for simultaneous imaging-guided therapy, which can materially shorten the evidence gap between target engagement and clinical effect. Therapeutic peptides focus on biological outcomes such as angiogenesis, anti-apoptotic signaling, or cardioprotection; angiogenic candidates often derive from fibroblast growth factor or vascular endothelial growth factor mimetics, while anti-apoptotic approaches involve either Bcl-2 modulators or caspase inhibitors and cardioprotective strategies address ischemia-reperfusion injury and myocardial infarction repair.

From an application perspective, the dominant use cases divide into diagnostic imaging, targeted drug delivery, and therapeutic treatment, and each application imposes distinct performance priorities. Diagnostic imaging workstreams differentiate among MRI, PET, and ultrasound modalities; MRI solutions frequently use gadolinium or iron oxide conjugates and emphasize relaxivity and retention, PET approaches rely on radionuclides such as fluorine-18 or gallium-68 and prioritize radiochemical stability, while ultrasound imaging can exploit microbubble-targeted peptides for high-resolution perfusion mapping. Targeted drug delivery spans hydrogel-based systems, liposomal delivery, and nanoparticle platforms; hydrogel approaches range from injectable to thermoresponsive formulations that enable localized depot formation, liposomal strategies include PEGylated and pH-sensitive variants to modulate circulation and release, and nanoparticle options use gold or iron oxide cores with differing shapes and surface chemistries to tune biodistribution. Therapeutic treatment areas such as arrhythmia control, heart failure management and myocardial infarction repair require different dosing paradigms, durability of effect, and safety profiles, with arrhythmia programs typically centered on antiarrhythmic peptides and heart failure approaches distinguishing between HFpEF and HFrEF biology.

End user segmentation further influences product design and commercial pathways because hospitals and clinics, pharmaceutical companies, and research institutes each have distinct procurement drivers and operational constraints. Cardiac specialty clinics and tertiary hospitals require device-compatible workflows, validated imaging protocols, and clear reimbursement rationales, whereas large pharmaceutical companies and biotech firms emphasize scalable manufacturing, regulatory precedent, and out-licensing potential. Research institutes, including both academic centers and contract research organizations, prioritize flexibility and translational capacity to support iterative optimization and early human studies. These different end users shape expected evidence packages, preferred delivery formats, and acceptable cost structures.

Lastly, delivery system and molecule type choices-spanning liposomal, nanoparticle, and polymer conjugates, as well as cyclic, dendrimer-based, and linear peptide architectures-drive both technical feasibility and IP strategy. Liposomal conjugates may be conventional or stealth, and modifications such as mannose targeting or PEGylation can materially alter biodistribution. Nanoparticle conjugates offer a broad set of core materials from gold to lipid- and polymer-based platforms, each with unique manufacturing and regulatory considerations. Polymer conjugates such as PEG and PLGA systems allow for controlled release and size-based targeting, while molecule type decisions-opting for cyclic versus linear constructs or leveraging dendrimer scaffolds-impact protease resistance, receptor binding, and synthetic complexity. Integrating segmentation insights across these axes enables teams to map program risks, prioritize experiments, and align commercial propositions with end user expectations.

Regional dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine clinical trial access, regulatory engagement, and commercialization pathways

Regional context matters because research intensity, regulatory regimes, commercial infrastructure, and reimbursement pathways vary across global markets and materially affect development and adoption strategies. In the Americas, a concentration of academic medical centers, specialized cardiac clinics, and a mature venture and pharmaceutical ecosystem accelerates translational work and facilitates access to clinical trial networks. Regulatory authorities in this region have well-established pathways for imaging agents and therapeutic peptides, and payers are increasingly receptive to technologies that demonstrate clear diagnostic value or reduce downstream interventions, which can shorten the route to commercial adoption for programs that produce robust clinical evidence.

Across Europe, Middle East & Africa, the landscape is heterogenous but rich in specialized clinical centers and collaborative research networks. Regulatory environments differ across jurisdictions, which means that cross-border development often requires tailored regulatory strategies and additional bridging studies. Reimbursement frameworks in many European markets emphasize health technology assessment and real-world effectiveness, prompting sponsors to plan longitudinal outcome measurements alongside traditional safety and efficacy endpoints. Market access in this combined region therefore benefits from early engagement with health authorities and payers to define value propositions that resonate with national systems.

The Asia-Pacific region combines high innovation capacity in select markets with rapidly expanding clinical trial infrastructure and manufacturing capabilities. Several countries in this region have developed strong peptide synthesis and biologics manufacturing clusters, which can be leveraged to reduce cost and accelerate production scale-up. Regulatory authorities are increasingly harmonizing standards and offering expedited pathways for novel therapies that address unmet needs, making Asia-Pacific an attractive geography both for clinical studies and for strategic manufacturing partnerships. Across all regions, local clinical practice patterns, physician training, and diagnostic infrastructure will influence technology uptake, so global strategies must blend centralized development with region-specific commercialization and evidence generation plans.

How corporate capabilities, partnership models, and intellectual property approaches shape competitive advantage and translational success in peptide development

Company strategies within the cardiac targeting peptide arena are differentiated by core capabilities, portfolio focus, and capital intensity. Large pharmaceutical organizations tend to integrate peptide programs into broader cardiovascular franchises, leveraging internal regulatory expertise, established manufacturing networks, and global commercialization channels to de-risk late-stage development. Mid-sized biotech firms and specialized startups often focus on platform technologies or niche indications where molecular design and formulation innovations can create defensible differentiation. These smaller entities typically prioritize early human proof of mechanism and then pursue partnerships or licensing transactions to secure resources for pivotal studies and commercialization.

Contract research and manufacturing organizations play a pivotal role by providing scalable peptide synthesis, conjugation expertise, and GLP/GMP capabilities that enable companies of all sizes to progress candidates without maintaining full in-house infrastructure. Academic spinouts and research institutes continue to be a rich source of novel targeting motifs and preclinical validation, but translating those discoveries requires careful attention to CMC (chemistry, manufacturing, and controls) planning and regulatory expectations.

Across the competitive landscape, companies are prioritizing strategic partnerships that accelerate translation: co-development agreements that combine imaging expertise with therapeutic know-how, supply agreements that secure critical excipients, and licensing deals that enable regional commercialization. Intellectual property strategies emphasize composition of matter for novel peptides, conjugation chemistries, and delivery platform optimizations. Firms that combine strong translational science with clear go-to-market plans-anticipating reimbursement and clinical workflow integration-are best positioned to convert technical promise into clinical impact and commercial viability.

Actionable recommendations for executives to prioritize programs, strengthen supply chains, and align regulatory and commercial strategies for accelerated impact

Industry leaders should adopt a dual-track strategy that balances near-term diagnostic and delivery opportunities with longer-term therapeutic ambitions. In pragmatic terms, prioritizing projects with clearer regulatory pathways-such as imaging agents and targeted delivery systems-can create early validation events and revenue pathways that support riskier therapeutic programs. Concurrently, investing in robust preclinical models and translational biomarkers will increase the probability that cardioprotective and angiogenic candidates demonstrate clinically meaningful signals.

Leaders must also fortify supply chain resilience by diversifying suppliers, qualifying alternative excipients, and negotiating flexible manufacturing agreements. Nearshoring or strategic stockpiling of critical inputs can blunt the impact of trade volatility. From a technology perspective, allocating resources to delivery system optimization-whether liposomal, nanoparticle, or polymer conjugates-will often yield higher returns than incremental molecule optimization alone, because delivery choices frequently dictate clinical performance and regulatory complexity.

Strategic partnerships are essential: co-development with imaging specialists, licensing collaborations with established cardiovascular franchises, and risk-sharing arrangements with payers or clinical networks can accelerate adoption. Finally, companies should engage early with regulators and payers to define acceptable evidence packages, incorporate patient-centered endpoints, and design clinical programs that demonstrate both short-term diagnostic utility and longer-term therapeutic benefit. Investing in talent, digital platforms for trial efficiency, and adaptive trial designs will further enhance execution capacity and shorten time to clinically meaningful readouts.

Description of the mixed methods research framework integrating primary interviews, literature review, patent mapping, regulatory analysis, and validation to ensure reliable findings

The research that underpins this analysis combined qualitative and quantitative approaches to ensure a robust, triangulated evidence base. Primary research included structured interviews with translational scientists, clinical investigators, manufacturing experts, and commercial leaders to capture first-hand perspectives on technical hurdles and strategic decision points. Secondary research encompassed a systematic review of peer-reviewed literature, clinical trial registries, patent landscapes, and regulatory guidance documents to validate claims and identify precedent pathways that influence development choices.

Analytical methods incorporated technology landscaping to map delivery platforms and molecule architectures, comparative regulatory analysis to highlight jurisdictional differences, and scenario planning to assess the operational impact of supply chain disruptions. Data validation steps included cross-referencing interview inputs with public filings and synthesizing disparate data points to produce coherent, reproducible findings. Where uncertainty remained, sensitivity assessments were performed to characterize the potential range of outcomes and to identify the variables with greatest leverage on program feasibility.

Limitations are acknowledged: evolving clinical data, emergent regulatory guidance, and dynamic trade policies can alter timelines and risk profiles. Therefore, readers are advised to use the insights as a strategic framework that should be complemented by project-specific due diligence and ongoing monitoring of regional regulatory and supply chain developments.

A concise conclusion synthesizing scientific advances, operational imperatives, and strategic priorities that determine success for cardiac targeting peptide programs

In summary, cardiac targeting peptides present a multifaceted opportunity space that links precision diagnostics, targeted delivery, and novel therapeutic modalities. Technical advances in molecular design, conjugation chemistries, and delivery platforms are converging to solve historical limitations around stability, biodistribution, and target specificity. At the same time, commercial and regulatory complexities require deliberate strategies to de-risk development and to demonstrate value to clinicians and payers.

Successful programs will combine rigorous translational science with pragmatic choices about application focus, delivery systems, and regional execution. Diagnostic and dual-function constructs offer a realistic route to early clinical validation, while therapeutic peptides addressing cardioprotection, angiogenesis, and anti-apoptotic pathways represent important but more demanding long-term opportunities. Supply chain resilience and strategic partnerships are non-negotiable operational components, particularly under the pressure of changing trade environments. By aligning scientific ambition with operational discipline and market insight, teams can increase the likelihood that promising molecules become clinically meaningful solutions for patients.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cardiac Targeting Peptides Market, by Product Type

  • 8.1. Diagnostics Peptides
    • 8.1.1. Biomarker Detection Agents
      • 8.1.1.1. Biosensor Probes
      • 8.1.1.2. Elisa Probes
    • 8.1.2. Imaging Agents
      • 8.1.2.1. Mri Contrast Peptides
      • 8.1.2.2. Pet Tracers
  • 8.2. Dual Function Peptides
    • 8.2.1. Drug Delivery Imaging Peptides
    • 8.2.2. Imaging Therapy Peptides
  • 8.3. Therapeutic Peptides
    • 8.3.1. Angiogenic Peptides
      • 8.3.1.1. Fgf Mimetic Peptides
      • 8.3.1.2. Vegf Mimetic Peptides
    • 8.3.2. Anti Apoptotic Peptides
      • 8.3.2.1. Bcl2 Modulating Peptides
      • 8.3.2.2. Caspase Inhibitor Peptides
    • 8.3.3. Cardioprotective Peptides
      • 8.3.3.1. Ischemia Reperfusion Injury Peptides
      • 8.3.3.2. Myocardial Infarction Peptides

9. Cardiac Targeting Peptides Market, by Delivery System

  • 9.1. Liposomal Conjugates
    • 9.1.1. Conventional Liposomes
      • 9.1.1.1. Cationic Liposomes
      • 9.1.1.2. Neutral Liposomes
    • 9.1.2. Stealth Liposomes
      • 9.1.2.1. Mannose Modified Liposomes
      • 9.1.2.2. PEGylated Liposomes
  • 9.2. Nanoparticle Conjugates
    • 9.2.1. Gold Nanoparticles
      • 9.2.1.1. Rod Shaped Gold Nanoparticles
      • 9.2.1.2. Spherical Gold Nanoparticles
    • 9.2.2. Lipid Nanoparticles
      • 9.2.2.1. Nanoemulsions
      • 9.2.2.2. Solid Lipid Nanoparticles
    • 9.2.3. Polymer Nanoparticles
      • 9.2.3.1. Chitosan Nanoparticles
      • 9.2.3.2. PLGA Nanoparticles
  • 9.3. Polymer Conjugates
    • 9.3.1. PEG Conjugates
      • 9.3.1.1. Branched PEG Conjugates
      • 9.3.1.2. Linear PEG Conjugates
    • 9.3.2. PLGA Conjugates
      • 9.3.2.1. Microparticles
      • 9.3.2.2. Nanoparticles

10. Cardiac Targeting Peptides Market, by Molecule Type

  • 10.1. Cyclic Peptides
    • 10.1.1. Disulfide Cyclized
      • 10.1.1.1. Mono Disulfide
      • 10.1.1.2. Multi Disulfide
    • 10.1.2. Head To Tail Cyclized
      • 10.1.2.1. Backbone Cyclized
      • 10.1.2.2. Side Chain Cyclized
  • 10.2. Dendrimer Based Peptides
    • 10.2.1. PAMAM Dendrimers
      • 10.2.1.1. Generation 4
      • 10.2.1.2. Generation 5
    • 10.2.2. PPI Dendrimers
      • 10.2.2.1. Generation 3
      • 10.2.2.2. Generation 4
  • 10.3. Linear Peptides
    • 10.3.1. Long Chain Peptides
      • 10.3.1.1. 21 To 50 Amino Acids
      • 10.3.1.2. >50 Amino Acids
    • 10.3.2. Short Chain Peptides
      • 10.3.2.1. 10 To 20 Amino Acids
      • 10.3.2.2. <10 Amino Acids

11. Cardiac Targeting Peptides Market, by Application

  • 11.1. Diagnostic Imaging
    • 11.1.1. Mri Imaging
      • 11.1.1.1. Gadolinium Conjugated Peptides
      • 11.1.1.2. Iron Oxide Conjugated Peptides
    • 11.1.2. PET Imaging
      • 11.1.2.1. Fluorine 18 Labeled Peptides
      • 11.1.2.2. Gallium 68 Labeled Peptides
    • 11.1.3. Ultrasound Imaging
  • 11.2. Targeted Drug Delivery
    • 11.2.1. Hydrogel Based Delivery
      • 11.2.1.1. Injectable Hydrogels
      • 11.2.1.2. Thermoresponsive Hydrogels
    • 11.2.2. Liposomal Delivery
      • 11.2.2.1. PEGylated Liposomes
      • 11.2.2.2. PH Sensitive Liposomes
    • 11.2.3. Nanoparticle Delivery
      • 11.2.3.1. Gold Nanoparticles
      • 11.2.3.1.1. Rod Shaped Gold Nanoparticles
      • 11.2.3.1.2. Spherical Gold Nanoparticles
      • 11.2.3.2. Iron Oxide Nanoparticles
  • 11.3. Therapeutic Treatment
    • 11.3.1. Arrhythmia Control
    • 11.3.2. Heart Failure Treatment
      • 11.3.2.1. Hfpef Treatment Peptides
      • 11.3.2.2. Hfref Treatment Peptides
    • 11.3.3. Myocardial Infarction Management
      • 11.3.3.1. Acute Mi Peptides
      • 11.3.3.2. Chronic Mi Repair Peptides

12. Cardiac Targeting Peptides Market, by End User

  • 12.1. Hospitals And Clinics
    • 12.1.1. Cardiac Specialty Clinics
      • 12.1.1.1. Outpatient Clinics
      • 12.1.1.2. Surgical Centers
    • 12.1.2. Tertiary Care Hospitals
      • 12.1.2.1. Private Hospitals
      • 12.1.2.2. Public Hospitals
  • 12.2. Pharmaceutical Companies
    • 12.2.1. Big Pharma
    • 12.2.2. Biotech Firms
      • 12.2.2.1. Mid Size Biotechs
      • 12.2.2.2. Small Biotechs
  • 12.3. Research Institutes
    • 12.3.1. Academic Institutions
      • 12.3.1.1. Government Labs
      • 12.3.1.2. Universities
    • 12.3.2. CROs
      • 12.3.2.1. Clinical CROs
      • 12.3.2.2. Preclinical CROs

13. Cardiac Targeting Peptides Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cardiac Targeting Peptides Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cardiac Targeting Peptides Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Cardiac Targeting Peptides Market

17. China Cardiac Targeting Peptides Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Acesion Pharma
  • 18.6. Amgen Inc.
  • 18.7. AstraZeneca PLC
  • 18.8. Bristol-Myers Squibb Company
  • 18.9. Eli Lilly and Company
  • 18.10. Ferring Pharmaceuticals Inc.
  • 18.11. Merck KGaA
  • 18.12. Novartis AG
  • 18.13. Novo Nordisk A/S
  • 18.14. Pfizer Inc.
  • 18.15. Sanofi S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CARDIAC TARGETING PEPTIDES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DELIVERY SYSTEM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CARDIAC TARGETING PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CARDIAC TARGETING PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTICS PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTICS PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTICS PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTICS PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY BIOMARKER DETECTION AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY BIOMARKER DETECTION AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY BIOMARKER DETECTION AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY BIOMARKER DETECTION AGENTS, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY BIOSENSOR PROBES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY BIOSENSOR PROBES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY BIOSENSOR PROBES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ELISA PROBES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ELISA PROBES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ELISA PROBES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY IMAGING AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY IMAGING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY IMAGING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY IMAGING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MRI CONTRAST PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MRI CONTRAST PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MRI CONTRAST PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PET TRACERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PET TRACERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PET TRACERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DUAL FUNCTION PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DUAL FUNCTION PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DUAL FUNCTION PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DUAL FUNCTION PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DRUG DELIVERY IMAGING PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DRUG DELIVERY IMAGING PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DRUG DELIVERY IMAGING PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY IMAGING THERAPY PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY IMAGING THERAPY PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY IMAGING THERAPY PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY THERAPEUTIC PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY THERAPEUTIC PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY THERAPEUTIC PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY THERAPEUTIC PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ANGIOGENIC PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ANGIOGENIC PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ANGIOGENIC PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ANGIOGENIC PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY FGF MIMETIC PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY FGF MIMETIC PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY FGF MIMETIC PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY VEGF MIMETIC PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY VEGF MIMETIC PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY VEGF MIMETIC PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ANTI APOPTOTIC PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ANTI APOPTOTIC PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ANTI APOPTOTIC PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ANTI APOPTOTIC PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY BCL2 MODULATING PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY BCL2 MODULATING PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY BCL2 MODULATING PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CASPASE INHIBITOR PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CASPASE INHIBITOR PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CASPASE INHIBITOR PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CARDIOPROTECTIVE PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CARDIOPROTECTIVE PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CARDIOPROTECTIVE PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CARDIOPROTECTIVE PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ISCHEMIA REPERFUSION INJURY PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ISCHEMIA REPERFUSION INJURY PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ISCHEMIA REPERFUSION INJURY PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MYOCARDIAL INFARCTION PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MYOCARDIAL INFARCTION PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MYOCARDIAL INFARCTION PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LIPOSOMAL CONJUGATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LIPOSOMAL CONJUGATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LIPOSOMAL CONJUGATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LIPOSOMAL CONJUGATES, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CONVENTIONAL LIPOSOMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CONVENTIONAL LIPOSOMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CONVENTIONAL LIPOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CONVENTIONAL LIPOSOMES, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CATIONIC LIPOSOMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CATIONIC LIPOSOMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CATIONIC LIPOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY NEUTRAL LIPOSOMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY NEUTRAL LIPOSOMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY NEUTRAL LIPOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY STEALTH LIPOSOMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY STEALTH LIPOSOMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY STEALTH LIPOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY STEALTH LIPOSOMES, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MANNOSE MODIFIED LIPOSOMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MANNOSE MODIFIED LIPOSOMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MANNOSE MODIFIED LIPOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PEGYLATED LIPOSOMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PEGYLATED LIPOSOMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PEGYLATED LIPOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY NANOPARTICLE CONJUGATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY NANOPARTICLE CONJUGATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY NANOPARTICLE CONJUGATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY NANOPARTICLE CONJUGATES, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GOLD NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GOLD NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GOLD NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GOLD NANOPARTICLES, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ROD SHAPED GOLD NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ROD SHAPED GOLD NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ROD SHAPED GOLD NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY SPHERICAL GOLD NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY SPHERICAL GOLD NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY SPHERICAL GOLD NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LIPID NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LIPID NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LIPID NANOPARTICLES, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY NANOEMULSIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY NANOEMULSIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY NANOEMULSIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY SOLID LIPID NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY SOLID LIPID NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY SOLID LIPID NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY POLYMER NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY POLYMER NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY POLYMER NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY POLYMER NANOPARTICLES, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CHITOSAN NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CHITOSAN NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CHITOSAN NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PLGA NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PLGA NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PLGA NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY POLYMER CONJUGATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY POLYMER CONJUGATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY POLYMER CONJUGATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY POLYMER CONJUGATES, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PEG CONJUGATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PEG CONJUGATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PEG CONJUGATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PEG CONJUGATES, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY BRANCHED PEG CONJUGATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY BRANCHED PEG CONJUGATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY BRANCHED PEG CONJUGATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LINEAR PEG CONJUGATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LINEAR PEG CONJUGATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LINEAR PEG CONJUGATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PLGA CONJUGATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PLGA CONJUGATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PLGA CONJUGATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PLGA CONJUGATES, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MICROPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MICROPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MICROPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CYCLIC PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CYCLIC PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CYCLIC PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY CYCLIC PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DISULFIDE CYCLIZED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DISULFIDE CYCLIZED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DISULFIDE CYCLIZED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DISULFIDE CYCLIZED, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MONO DISULFIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MONO DISULFIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MONO DISULFIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MULTI DISULFIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MULTI DISULFIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MULTI DISULFIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY HEAD TO TAIL CYCLIZED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY HEAD TO TAIL CYCLIZED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY HEAD TO TAIL CYCLIZED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY HEAD TO TAIL CYCLIZED, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY BACKBONE CYCLIZED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY BACKBONE CYCLIZED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY BACKBONE CYCLIZED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY SIDE CHAIN CYCLIZED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY SIDE CHAIN CYCLIZED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY SIDE CHAIN CYCLIZED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DENDRIMER BASED PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DENDRIMER BASED PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DENDRIMER BASED PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DENDRIMER BASED PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PAMAM DENDRIMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PAMAM DENDRIMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PAMAM DENDRIMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PAMAM DENDRIMERS, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GENERATION 4, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GENERATION 4, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GENERATION 4, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GENERATION 5, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GENERATION 5, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GENERATION 5, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PPI DENDRIMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PPI DENDRIMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PPI DENDRIMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PPI DENDRIMERS, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GENERATION 3, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GENERATION 3, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GENERATION 3, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GENERATION 4, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GENERATION 4, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GENERATION 4, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LINEAR PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LINEAR PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LINEAR PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LINEAR PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LONG CHAIN PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LONG CHAIN PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LONG CHAIN PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LONG CHAIN PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY 21 TO 50 AMINO ACIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY 21 TO 50 AMINO ACIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY 21 TO 50 AMINO ACIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY >50 AMINO ACIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY >50 AMINO ACIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY >50 AMINO ACIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY SHORT CHAIN PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY SHORT CHAIN PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY SHORT CHAIN PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY SHORT CHAIN PEPTIDES, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY 10 TO 20 AMINO ACIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY 10 TO 20 AMINO ACIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 223. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY 10 TO 20 AMINO ACIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY <10 AMINO ACIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY <10 AMINO ACIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 226. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY <10 AMINO ACIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 227. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTIC IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 229. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTIC IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 230. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTIC IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 231. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 232. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MRI IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 233. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MRI IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 234. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MRI IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY MRI IMAGING, 2018-2032 (USD MILLION)
  • TABLE 236. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GADOLINIUM CONJUGATED PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 237. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GADOLINIUM CONJUGATED PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 238. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GADOLINIUM CONJUGATED PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 239. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY IRON OXIDE CONJUGATED PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 240. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY IRON OXIDE CONJUGATED PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 241. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY IRON OXIDE CONJUGATED PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 242. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PET IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 243. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PET IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 244. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PET IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 245. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PET IMAGING, 2018-2032 (USD MILLION)
  • TABLE 246. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY FLUORINE 18 LABELED PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 247. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY FLUORINE 18 LABELED PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 248. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY FLUORINE 18 LABELED PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 249. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GALLIUM 68 LABELED PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 250. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GALLIUM 68 LABELED PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 251. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GALLIUM 68 LABELED PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 252. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ULTRASOUND IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 253. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ULTRASOUND IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 254. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY ULTRASOUND IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 255. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY TARGETED DRUG DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 256. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY TARGETED DRUG DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 257. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY TARGETED DRUG DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 258. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY TARGETED DRUG DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 259. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY HYDROGEL BASED DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 260. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY HYDROGEL BASED DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 261. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY HYDROGEL BASED DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY HYDROGEL BASED DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 263. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY INJECTABLE HYDROGELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 264. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY INJECTABLE HYDROGELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 265. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY INJECTABLE HYDROGELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 266. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY THERMORESPONSIVE HYDROGELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 267. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY THERMORESPONSIVE HYDROGELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 268. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY THERMORESPONSIVE HYDROGELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 269. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LIPOSOMAL DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 270. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LIPOSOMAL DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 271. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LIPOSOMAL DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 272. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY LIPOSOMAL DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 273. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PEGYLATED LIPOSOMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 274. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PEGYLATED LIPOSOMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 275. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PEGYLATED LIPOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 276. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PH SENSITIVE LIPOSOMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 277. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PH SENSITIVE LIPOSOMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 278. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY PH SENSITIVE LIPOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 279. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY NANOPARTICLE DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 280. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY NANOPARTICLE DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 281. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY NANOPARTICLE DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 282. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 283. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE, BY GOLD NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 284. GLOBAL CARDIAC TARGETING PEPTIDES MARKET SIZE